The U.S. Supreme Court said it will rule in a case involving payments by pharmaceutical companies to rivals in return for delaying sales of generic drugs.
The Federal Trade Commission says the so-called pay-for-delay deals violate antitrust law, preserve monopolies and artificially jack up prices, the Los Angeles Times said Saturday.
The commission said 28 such agreements cost consumers and taxpayers at least $3.5 billion in 2011, the newspaper reported.
"When drug companies agree not to compete, consumers lose," FTC Chairman Jon Leibowitz said.
Federal courts have upheld such deals in a number of cases, finding they constitute settlements of patent disputes.
The Supreme Court said Friday it would consider a case involving an agreement in which Solvay Pharmaceuticals Inc., which makes the testosterone booster AndroGel, agreed to pay Watson Pharmaceuticals Inc. more than $19 million a year in return for Watson's agreement to hold a competitive drug off the market until 2015.
Most Popular Stories
- Study: Recessions Can Postpone Motherhood Forever
- Hispanic Entrepreneurs Short-changed in Texas
- Hispanics Carry Big Clout: Census
- Washington's 'The Equalizer' Debuts With $35 Million
- Effort to Oust Assad Put on Hold
- Tim Cook Has Proved That Apple is His Baby
- Who Is Daniel Ivascyn?
- Qantas Puts World's Largest Plane on Longest Route
- Los Angeles Set to Host Small Business Summit
- Chicago Flight Delays: Questions Answered